Take Solutions (TAKE)
TurnaroundScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹23.76 |
| Market Cap | ₹347.43 Cr |
| P/E Ratio | 81.93 |
| ROCE | 11.24% |
| ROE | 1.04% |
| Dividend Yield | 0% |
| Profit Growth | 0% |
| Debt/Equity | — |
| Sales Growth | 0% |
| Promoter Holding | 0% |
| 52-Week Range | ₹10.09 — ₹50.14 |
| Sector | Healthcare Services |
| Book Value | ₹20.12 |
Strengths
- ROCE of 11.24% suggests some operating capital efficiency despite poor equity returns.
- Latest quarter net profit is positive at ₹1 Cr.
- Book value per share is positive at ₹20.12, offering a tangible asset base.
Concerns
- P/E near 1,000 with profit growth of -77.35% shows extreme valuation disconnect from earnings.
- Promoter holding of 0.00% means no skin in the game.
- Latest quarter sales of ₹0 Cr indicate core revenue has dried up; Piotroski F-score of 3/9 is weak.
- Dividend yield is 0.00% and debt-to-equity is not disclosed, leaving balance sheet risk unknown.
AI Analysis
I start with the rule that a great business must be able to earn more than pocket change on the capital it employs. Take Solutions fails that test: ROE is just 1.04%, so every hundred rupees of book value earns only one rupee. The latest quarter brings zero sales and one crore profit—that resembles a windfall, not a franchise. Selling at ₹47.20, the market capitalizes this at ₹625 Cr, or 2.35 times a ₹20.12 book value. A P/E near 1,000 and a year-on-year profit fall of 77.35% tell me the market is paying for a story, not numbers. I also see promoter holding of 0.00%. In India and everywhere else, I want owners who eat their own cooking; an empty promoter box is a giant red flag. The Piotroski F-score of 3/9 supports the idea that financial health is decaying. Dividend yield of 0.00% means I won't get paid to wait. Graham taught me to weigh facts, not hopes. There is one positive: ROCE at 11.24% is respectable, and the company did earn a small profit in the latest quarter. But that is nowhere near enough. The price has travelled from ₹9.54 to ₹50.14, so traders have been excited. As an investor, I cannot rely on momentum. I need revenue traction, margin stability, and a balance sheet I can see. The debt-to-equity figure is not provided, so I am blind on leverage. This looks far more like a speculative turnaround than an established compounder. In my circle of competence, I pass. Better to miss a miracle than to lose money waiting for it.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer